PSORIATIC ARTHRITIS TREATMENT MARKET ANALYSIS

Global psoriatic arthritis treatment market growth can be hampered due to high treatment costs associated with biologic drugs that are primarily used for effective treatment of the disease. Psoriatic arthritis, being a chronic and progressive autoimmune disease, requires long-term treatment often lasting for many years. The currently available biologic drugs that target specific molecules like TNF-alpha and IL proteins are very effective but also expensive, with an average annual cost of therapy ranging from US$ 20,000 to US$ 50,000 per patient. This makes such treatments largely inaccessible for a huge population globally. The development of cheaper generic versions called biosimilars can help lower the costs but these still remain significantly higher than traditional DMARDs. High cost of disease management poses a major barrier in ensuring effective treatment for all patients suffering from psoriatic arthritis worldwide.

Market Opportunity - Development of Biosimilars

Global psoriatic arthritis treatment market can offer growth opportunities due to development of biosimilar drugs. Biosimilars are essentially cheaper generic versions of original patented biologics whose patents have expired. With patents of some major blockbuster biologics like Humira, Remicade and Enbrel expiring in the next few years, numerous pharma companies are in the race to develop high quality biosimilars for these drugs. This can significantly lower treatment costs, with biosimilars likely being priced 20-30% lower than originator biologics. Increased adoption of such lower-cost biosimilars can enhance affordability and accessibility of biologic treatment regimens for psoriatic arthritis patients globally. It will also offer pharma companies an attractive revenue opportunity in the market.